GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
NCT04731272 on ClinicalTrials.gov · last registry update 2026-05-18
A small phase 2 — 30 participants, against a typical 110. Due to report 30 June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Early-phase insulin secretion. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 16 July 2021 — 5 years so far. dulaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- dulaglutideTrulicity
- Sponsor
- University of Pennsylvania
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2021-07-16
- Primary completion
- 2027-06-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Early-phase insulin secretion
Conditions studied
Cystic Fibrosis · Pancreatic Insufficiency · Abnormal Glucose Tolerance · Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.